Drug Pipeline

INCA033989 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
1
Phase 3
1
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-09 NCT07448155
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989…		 date change Primary completion pushed: 2026-05-23 -> 2026-10-19
2026-06-09 NCT07448155
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989…		 date change Completion pushed: 2026-05-23 -> 2026-10-19
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-03 NCT07623200 A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With… Phase 3 Not Yet Recruiting
Active Studies by Phase
Phase 3
1
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07623200 A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With… Essential Thrombocythemia Not Yet Recruiting
Phase 1
NCT05936359 A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With… Myeloproliferative Neoplasms Recruiting
NCT06034002 A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With… Myeloproliferative Neoplasms Recruiting
NCT07448155 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989… Healthy Participants Active, Not Recruiting
Sponsors Running INCA033989 Trials
Incyte Corporation (4)
Disease Areas
Myelofibrosis (2)
Get alerts when INCA033989 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free